Skip to main content
Premium Trial:

Request an Annual Quote

Metabolon Strikes Biomarker Discovery Partnership With Cleveland Clinic

NEW YORK — Metabolon said on Thursday that it has signed an agreement to support drug development and related research at the Cleveland Clinic.

Under the terms of the deal, Metabolon will apply its Precision Metabolomics liquid chromatography-mass spectrometry global metabolomics platform — which identifies pharmacodynamic, efficacy, and response biomarkers and tracks changes in biological pathways — to large-scale population health programs underway at the Cleveland Clinic.

Metabolon said that it aims to analyze a range of biological samples to discover metabolomic biomarkers that can help inform these research efforts.

Additional terms of the deal were not disclosed.

"Metabolomics is an essential element of the multi-omics approach that is being employed by Cleveland Clinic to transform healthcare by understanding disease progression and therapeutic response more deeply," Metabolon Scientific Director Greg Michelotti said in a statement.

In August, Morrisville, North Carolina-based Metabolon inked a deal to use its Precision Metabolomics platform to advance drug-development work at Germany's Merck KGaA.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.